IN VIVO Blog readers are the smartest blog readers in the world (it's true, we read it on Wikipedia) and therefore when more than 50% of you are currently suggesting in our poll that Pfizer's planned $68 billion acquisition of Wyeth is a bad deal for both companies, we assume you've got ideas of your own on how to spend $68 billion.
Ask Monty Brewster: spending that kind of dough is definitely not easy. So how would we do it? Your IN VIVO Blog team came up with a few suggestions, just as we did for Roche back in the summer of '08.
Any ideas of your own? Lets see them in the comments. For the record, buying 68 billion hot dogs on dollar-dog-night at your local ballpark is already taken. Pig.
- Bail out California. According to the Governator: "The $42 billion deficit is a rock upon our chest and we cannot breathe until we get it off." HELP CALIFORNIA BREATHE!
- Smaller, targeted acquisitions is a popular idea among your IV Blog staff. Want to bulk up in Alzheimer's? Buy Elan for half of bapinuzumab. Or, there are a handful of start-ups ripe for the taking. Vaccines? Why not buy Crucell, as Wyeth was planning to do. Oncology? Celgene. Platform? Alnylam! The list goes on and on.
- Sign Manny Ramirez to a four-year deal to play LF for company softball team. (That's just "Pfizer being Pfizer".)
- Continue the risk/profit sharing most notably defined by the Pfizer/BMS deal on apixiban with a large group of other companies--say, a dozen. That leaves about $50 billion to chip in elsewhere. You know, pocket change.
- Buy 38 billion 8 oz. boxes of Kraft macaroni & cheese (dino-shapes optional) as comfort food for the newly unemployed.